Neurocrine Biosciences Inc vs Navitas Semiconductor Corporation Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while Navitas Semiconductor Corporation Common Stock trades at $11.19 (market cap $2.97B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.9× Navitas Semiconductor Corporation Common Stock's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Navitas Semiconductor Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Navitas Semiconductor Corporation Common Stock for 0 Days on average.
| NBIX | NVTS | |
|---|---|---|
Market Cap | $14.60B | $2.97B |
Volume | 1,075,694 | 18,229,864 |
Sector | Health | Technology |
52-Week High | $185.50 | $31.79 |
52-Week Low | $123.10 | $7.14 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $14.61B | $2.41B |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Navitas Semiconductor designs and markets gallium nitride and silicon carbide power semiconductors. Its products are used in power conversion and charging for data centers, energy infrastructure, and industrial applications.
Read more on NVTS →